A streamlined workflow for the determination of the drug-to-antibody ratio (DAR) of antibody-drug conjugates (ADCs)

In this application note, Intabio highlights an efficient intact protein analysis workflow for determining drug-to-antibody ratios (DARs) of antibody-drug conjugates (ADCs). This workflow leverages high-resolution mass spectrometry (MS) for accurate intact mass measurement in addition to automated protein deconvolution and DAR calculation provided by Biologics Explorer software. Average DAR values of 3.6 and 3.5 were obtained for the glycosylated (native) and deglycosylated forms of trastuzumab emtansine (T-DM1), respectively.